John Rex

John Rex

Scientific Advisory Board

Infectious Diseases

VP and Head of Infection, Global Medicines Development, AstraZeneca.

25 years of drug development experience, including 15 years as an academic investigator (National Institutes of Health, Bethesda, Maryland; University of Texas Medical School-Houston).

Since September 2012 Non-Executive Director at F2G Ltd, a UK-based biotechnology company dedicated to the discovery and development of compounds to treat life-threatening systemic fungal infections.